ReviewCancers2025
Guidance for the Clinical Use of the Breast Cancer Polygenic Risk Scores.
Abstract readReview
In one paragraph
Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Hereditary cancer: Germline testing practices across ERN GENTURIS member countries.European journal of human genetics : EJHG · 2026Article
- Understanding patient perspectives on breast cancer risk: a qualitative study to inform genetic testing communication in the primary care setting.Journal of community genetics · 2026Article
- A mixed-methods exploration of stakeholder experiences and perspectives on integrating polygenic breast cancer risk scores into Swedish clinical practice.BMC health services research · 2026Article
- Germline Multigene Panel Testing in Women With Invasive Lobular Cancer.JAMA network open · 2026Article
- Patient Perspectives on Psychiatric Polygenic Risk Scores in Reproductive Decision-Making and Polygenic Embryo Screening.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics · 2026Article
- Multi-omics analysis in suspected hereditary breast and ovarian cancer cases reveals novel candidate susceptibility factors.NPJ breast cancer · 2026Article
- Are polygenic scores for psychiatric and substance use outcomes "ready" for clinical application? Current state and next steps.Psychiatric genetics · 2026Review
- Polygenic risk scores (PRS) in society. Healthcare providers and researchers' views on the public health and socio-cultural implications of PRS in healthcare contexts.Journal of community genetics · 2026Article
- Polygenic risk scores: Navigating the future of precision medicine through economic, ethical, and scientific advancements.iScience · 2026Review
- Predictive Biomarkers for Asymptomatic Adults: Opportunities, Risks, and Guidance for General Practice.Diagnostics (Basel, Switzerland) · 2026Review
- Implementing polygenic risk-based breast cancer screening across European health systems: insights from the BRIGHT project.Frontiers in health services · 2026Article
- Polygenic risk scores in healthcare contexts: what's the scope? An interview study of European healthcare providers and researchers' perspectives on ethical challenges.Human genetics · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Peeter PadrikClinic of Hematology and Oncology, Tartu University Hospital, 50603 Tartu, Estonia.
Neeme TõnissonInstitute of Genomics, University of Tartu, 51010 Tartu, Estonia.ORCID 0000-0002-1715-3164
Tone HovdaDepartment of Radiology, Vestre Viken Hospital Trust, 3004 Drammen, Norway.
Kristine Kleivi SahlbergDepartment of Research and Innovation, Vestre Viken Hospital Trust, 3004 Drammen, Norway.
Eivind HovigDepartment of Tumor Biology, Institute of Cancer Research, Oslo University Hospital, 0424 Oslo, Norway.ORCID 0000-0002-9103-1077
Luís CostaHospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, 1649-028 Lisbon, Portugal.
Gonçalo Nogueira da CostaHospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, 1649-028 Lisbon, Portugal.ORCID 0000-0002-1127-052X
Inna FeldmanDepartment of Public Health and Caring Sciences, Uppsala University, 753 10 Uppsala, Sweden.
Filipa SampaioDepartment of Public Health and Caring Sciences, Uppsala University, 753 10 Uppsala, Sweden.ORCID 0000-0002-5540-9853
Sander PajusaluGenetics and Personalized Medicine Clinic, Tartu University Hospital, 50406 Tartu, Estonia.ORCID 0000-0002-5435-0781
Kristiina OjamaaClinic of Hematology and Oncology, Tartu University Hospital, 50603 Tartu, Estonia.
Kersti KallakClinic of Hematology and Oncology, Tartu University Hospital, 50603 Tartu, Estonia.
Ave-Triin TihamäeClinic of Surgery, Tartu University Hospital, 50406 Tartu, Estonia.
Laura RohtGenetics and Personalized Medicine Clinic, Tartu University Hospital, 50406 Tartu, Estonia.ORCID 0000-0002-5727-6759
Tiina KahreGenetics and Personalized Medicine Clinic, Tartu University Hospital, 50406 Tartu, Estonia.ORCID 0009-0007-4399-354X
Anni LeplandGenetics and Personalized Medicine Clinic, Tartu University Hospital, 50406 Tartu, Estonia.
Siim SõberOÜ Antegenes, 50603 Tartu, Estonia.
Krista Kruuv-KäoOÜ Antegenes, 50603 Tartu, Estonia.ORCID 0009-0001-8627-6993
Madli TammInstitute of Genomics, University of Tartu, 51010 Tartu, Estonia.ORCID 0000-0003-4942-9572
Jajini VargheseRoyal Free London NHS Trust, UCL Division of Surgery and Interventional Sciences, London NW3 2QG, UK.ORCID 0000-0001-8189-5608
Dafydd Gareth EvansManchester Centre for Genomic Medicine, Division of Evolution, Infection, and Genomic Sciences, University of Manchester, Manchester M13 9PL, UK.ORCID 0000-0002-8482-5784
AnteNOR and BRIGHT Research Consortia
Funding
BRIGHT consortium by European Commission via EIT Health BRIGHT innovation activity project #230121D Gareth Evans is supported by the Manchester National Institute for Health Research (NIHR) Biomedical Research Centre IS-BRC-1215-20007Sander Pajusalu is supported by the Estonian Research Council grant PSG774The AnteNOR consortium was sponsoring the development of the guidance through a grant from the Norwegian Grants 2014-2021 Green ICT programme Project No 2014-2021.1.02.20-0113
Abstract
PubMed holds no abstract for this paper.
Indexed as
breast cancergenetic predispositionpersonalised medicinepolygenic risk scorepreventionscreening
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.